SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Noked Israel Ltd

CIK 0001767750 · 22 HAGEFEN ST, RAMAT HASHARON, L3, 4725422 · 972-73-780-3400

Reported Value
$56M
Q1 2020
Positions
14
Filings on Record
32
2019–present window
Filed
May 27, 2020
amendment (RESTATEMENT)

Summary

Noked Israel Ltd reported $56M in U.S.-listed holdings across 14 positions for Q1 2020.

The portfolio is heavily concentrated: TEVA alone accounts for 41.6% of reported value.

Compared with Q4 2019, the fund opened 6 new positions and exited 50.

Portfolio Metrics

Turnover
+48.1%
vs prior filed quarter
Top-10 Concentration
+97.9%
share of reported value
Largest Position
+41.6%
Teva Pharmaceutical Inds
New / Exited
6 / 50
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $96MQ1 ’19Q2 ’19: $82MQ3 ’19: $95MQ4 ’19: $89MQ1 ’20: $56MQ1 ’20Q2 ’20: $140MQ3 ’20: $151MQ4 ’20: $243MQ1 ’21: $307MQ1 ’21Q2 ’21: $401MQ3 ’21: $425MQ4 ’21: $407MQ1 ’22: $329MQ1 ’22Q2 ’22: $435MQ3 ’22: $411MQ4 ’22: $262MQ1 ’23: $230MQ1 ’23Q2 ’23: $292MQ3 ’23: $330MQ4 ’23: $379MQ1 ’24: $372MQ1 ’24Q2 ’24: $362MQ3 ’24: $458MQ4 ’24: $508MQ1 ’25: $436MQ1 ’25Q2 ’25: $542MQ3 ’25: $639MQ4 ’25: $624MQ1 ’26: $677MQ1 ’26filingsflow.com

Portfolio Composition

By security type
ADR: 44.3%Common Stock: 40.1%Other: 15.6%
  • ADR · 44.3% · $25M
  • Common Stock · 40.1% · $22M
  • Other · 15.6% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TEVATEVA PHARMACEUTICAL INDS LTDNEW+2.60M2.60M+$23M$23M
NTRNUTRIEN LTDNEW+90.0K90.0K+$3M$3M
ORAORMAT TECHNOLOGIES INCNEW+30.0K30.0K+$2M$2M
BABAALIBABA GROUP HLDG LTDNEW+6.9K6.9K+$1M$1M
SAPIENS INTL CORP N VNEW+24.6K24.6K+$469,000$469,000
ITMRITAMAR MED LTDNEW+14.8K14.8K+$174,000$174,000
RADA ELECTR INDS LTDADDED+1.20M1.45M+$4M$5M
AMZNAMAZON COM INCADDED+380670+$770,000$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

14 positions
#IssuerClass% PortfolioValueShares
1TEVATEVA PHARMACEUTICAL INDS LTDhistory →SPONSORED ADS41.62%$23M2.60M
2SEDGSOLAREDGE TECHNOLOGIES INChistory →COM17.77%$10M121.5K
3MSFTMICROSOFT CORPhistory →COM10.89%$6M38.7K
4RADA ELECTR INDS LTDCOM PAR NEW9.08%$5M1.45M
5NTRNUTRIEN LTDhistory →COM5.46%$3M90.0K
6ORAORMAT TECHNOLOGIES INChistory →COM3.63%$2M30.0K
7CIM COML TR CORPCOM NEW2.40%$1M121.4K
8BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS2.40%$1M6.9K
9G WILLI FOOD INTL LTDORD2.35%$1M117.3K
10AMZNAMAZON COM INChistory →COM2.33%$1M670
11SAPIENS INTL CORP N VSHS0.84%$469,00024.6K
12ELLOMAY CAPITAL LTDSHS0.51%$284,00020.0K
13XTL BIOPHARMACEUTICALS LTDSPONSORED ADR NE0.42%$234,000198.9K
14ITMRITAMAR MED LTDSPONSORED ADS0.31%$174,00014.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$677M13May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$624M14Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$639M14Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$542M12Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$436M15May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$508M16Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$458M18Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$362M15Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$372M22May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$379M31Feb 15, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$330M28Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$292M35Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$230M22May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M27Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$411M50Dec 27, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$435M48Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$329M42May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$407M45Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$425M46Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$401M35Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$307M33May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$243M27Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$151M22Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$140M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$56M14May 27, 2020RESTATEMENTchanges · EDGAR ↗
Q4 2019$89M58Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$95M38Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$82M81Aug 15, 201913F-HRchanges · EDGAR ↗
Q1 2019$96M72May 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.